Reviewed by The Peptide Dispatch Editorial Team · Last reviewed July 6, 2026
Sermorelin (SERM) is a growth hormone peptide, at the fda approved (diagnostic) stage in the published literature. The first 29 amino acids of natural GHRH, providing physiological GH release patterns. FDA approved for GH deficiency diagnosis.
The first 29 amino acids of natural GHRH, providing physiological GH release patterns. FDA approved for GH deficiency diagnosis.
| Research Status | FDA approved (diagnostic) |
|---|---|
| Half-Life | 10-20 minutes |
| Administration | Subcutaneous injection |
| Doses Reported in Published Studies | 100-300 mcg |
Natural GHRH fragment that stimulates pituitary GH release in a physiological pulsatile pattern.
The first 29 amino acids of natural GHRH, providing physiological GH release patterns. FDA approved for GH deficiency diagnosis.
Natural GHRH fragment that stimulates pituitary GH release in a physiological pulsatile pattern.
Sermorelin is at the following stage in the published literature: FDA approved (diagnostic). All information is for research and educational purposes only.
Reported half-life: 10-20 minutes.
Reported administration route in the literature: Subcutaneous injection. This is not a recommendation for human use.
Educational content, not medical advice. Effects described are drawn from cited research in study subjects.